Education
About Us
Working with TipRanks
Follow Us
Nevro Corp (NVRO)
NYSE:NVRO
NVRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.17 - $13.84
Previous CloseN/A
Volume192.24K
Average Volume (3M)1.28M
Market Cap
$224.09M
Enterprise Value$178.54M
Total Cash (Recent Filing)-$30.61M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Apr 30, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding38,372,025
10 Day Avg. Volume1,258,594
30 Day Avg. Volume1,276,409
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.54
Price to Cash Flow (P/CF)2.90
P/FCF Ratio2.90
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.66
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$5.85Price Target Upside0.17% Upside
Rating ConsensusHold
Number of Analyst Covering9
---
Nevro Corp News
---
Bulls Say, Bears Say
Bulls Say
AcquisitionNevro Corp announced an agreement to be acquired by GMED for $5.85/share, which represents a 17% premium to its undisturbed closing price.
Financial PerformanceQ4 preliminary results ahead of consensus: NVRO announced that it expects Q4/24 revenue in the range of $105M-$106M, ahead of our $98.6M estimate and the Street’s $100.2M.
SynergiesGMED sees potential revenue synergies by leveraging its position with spine and neurosurgeons to grow the spinal cord stimulation business.
Bears Say
CompetitionNevro Corp had a large downward revision to guidance due to increased competition and physicians choosing companies with a broader spectrum of products.
Market ChallengesThere are ongoing challenges in the spinal cord stimulation market, including increased competitive dynamics and market softness.
Revenue HeadwindsRevenue headwinds expected to persist into 2025 with NVRO citing competition/new product trialing as well as changes to commercial team and optimization of sales territories.
---
Ownership Overview
4.69% Insiders
19.94% Mutual Funds
47.11% Other Institutional Investors
17.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVRO FAQ
What was Nevro Corp’s price range in the past 12 months?
Nevro Corp lowest stock price was $3.17 and its highest was $13.84 in the past 12 months.
What is Nevro Corp’s market cap?
Nevro Corp’s market cap is $224.09M.
When is Nevro Corp’s upcoming earnings report date?
Nevro Corp’s upcoming earnings report date is Apr 30, 2025 which is in 27 days.
How were Nevro Corp’s earnings last quarter?
Nevro Corp released its earnings results on Mar 04, 2025. The company reported -$1.41 earnings per share for the quarter, missing the consensus estimate of -$0.768 by -$0.642.
Is Nevro Corp overvalued?
According to Wall Street analysts Nevro Corp’s price is currently Undervalued.
Does Nevro Corp pay dividends?
Nevro Corp does not currently pay dividends.
What is Nevro Corp’s EPS estimate?
Nevro Corp’s EPS estimate is -0.85.
How many shares outstanding does Nevro Corp have?
Nevro Corp has 38,372,025 shares outstanding.
What happened to Nevro Corp’s price movement after its last earnings report?
Nevro Corp reported an EPS of -$1.41 in its last earnings report, missing expectations of -$0.768. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Nevro Corp?
Currently, no hedge funds are holding shares in NVRO
---
Nevro Corp Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.85 (0.17% Upside)
$5.85 (0.17% Upside)
Blogger Sentiment
Bullish
NVRO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-56.15%
12-Months-Change
Fundamentals
Return on Equity
-43.28%
Trailing 12-Months
Asset Growth
-12.88%
Trailing 12-Months
Company Description
Nevro Corp
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
---
NVRO Company Deck
---
NVRO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in cost management, cash position improvement, and new product launches like HFX AdaptivAI, which show promise for future growth. However, the company faced challenges with declining revenue and trial procedures, competitive pressures, and international market issues. While the company is optimistic about its strategic initiatives and new technology, market challenges remain a concern.Read More>---
NVRO Stock 12 Month Forecast
Average Price Target
$5.85
▲(0.17% Upside)
Technical Analysis
Best Analysts Covering NVRO
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+38.45%
reiterated a sell rating 7 months ago
Copying Travis Steed's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +38.45% per trade.
---